Clinical trial
A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-Globin
NCT05015920 is registered in ClinicalTrials.gov with Shanghai BDgene Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-Globin
- Lead sponsor
- Shanghai BDgene Co., Ltd.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- July 10, 2021
- Completion date
- December 31, 2024
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.